

## **ChromaDex to Report Third Quarter Financial Results on Wednesday, November 2, 2022**

LOS ANGELES – ChromaDex Corp. (NASDAQ:CDXC) (“the Company”), a global bioscience company dedicated to healthy aging, announced that it will hold a conference call on Wednesday, November 2, 2022 at 4:30 p.m. ET to discuss its financial results for the third quarter, which ended September 30, 2022. The financial results will be reported in a press release after the close of regular stock market trading hours on the same day as the conference call.

### **Investor Conference Call:**

ChromaDex management will host an investor conference call to discuss the third quarter results and provide a general business update on Wednesday, November 2, 2022 at 4:30 p.m. ET.

Participants should call in at least 10 minutes prior to the call. The dial-in information is as follows:

Date: Wednesday, November 2, 2022

Time: 4:30 p.m. ET (1:30 p.m. PT)

Toll-free dial-in number: 1-888-330-2446

Conference ID: 4126168

Webcast link: ChromaDex Third Quarter 2022 Earnings Conference Call

The conference call will be broadcast live and available for replay here and via the investor relations section of ChromaDex’s website at [www.chromadex.com](http://www.chromadex.com).

A replay of the conference call will be available from 7:30 p.m. ET on November 2, 2022, to 11:59 p.m. ET on November 9, 2022.

Toll-free replay number: 1-800-770-2030

Replay ID: 4126168

### **Forward Looking Statements:**

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of

1934, as amended. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as “expects,” “anticipates,” “intends,” “estimates,” “plans,” “potential,” “possible,” “probable,” “believes,” “seeks,” “may,” “will,” “should,” “could” or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the impact of the COVID-19 pandemic on our business and the global economy; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex’s Annual Report on Form 10-K for the fiscal year ended December 31, 2021, ChromaDex’s Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC’s website at [www.sec.gov](http://www.sec.gov). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.

### **About ChromaDex:**

ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen®. Nicotinamide riboside and other NAD+ precursors are protected by ChromaDex’s patent portfolio. ChromaDex maintains a website at [www.chromadex.com](http://www.chromadex.com) to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.

View source version on [businesswire.com](http://businesswire.com):

<https://www.businesswire.com/news/home/20221026005338/en/>

### **ChromaDex Media Contact:**

Kendall Knysch, Director of Media Relations

310-388-6706 ext. 689

kendall.knysch@chromadex.com

**ChromaDex Investor Relations Contact:**

Tom Shumaker, LifeSci Advisors, Managing Director

1-917-929-7600

tshumaker@lifesciadvisors.com